Compass pathways stock forecast.

According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebThat's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).Check out our CMPS stock analysis, current CMPS quote, charts, and historical prices for COMPASS Pathways Plc - American Depository Shares stock.

Discover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.

COMPASS Pathways (CMPS) Insider Trading Activity 2023. S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) 13 crew members missing after a cargo ship …

A live webcast of the call will be available on COMPASS Pathway’s website at: First Quarter 2023 Financial Results. The webcast will also be available on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. The call will also be webcast on the COMPASS Pathways website and archived for 30 days.WebAbout CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.On May 2, COMPASS Pathways (CMPS 6.61%) announced that the American Medical Association (AMA) ... This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock.

Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ...

Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 …Latest CMPS News. View. COMPASS Pathways (CMPS, $5.98) entered Downtrend as Momentum indicator drops below 0 level on Nov 30, 2023. Tickeron - Stocks • 3 days ago. Compass Pathways to participate in upcoming Evercore investor conference. Globe Newswire • 10 days ago.WebPrice vs Fair Value View History CMPS is trading at a 62% discount. Price $5.94 Nov 17, 2023 Fair Value $72.99 Nov 17, 2023 Uncertainty Extreme 1-Star Price $86.85Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.Web

Jul 6, 2023 · The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC. On Nov 02, 2023, Compass Pathways ( NASDAQ: CMPS) reported Q3 2023 earnings per share (EPS) of -$0.67, up 55.81% year over year. Total Compass Pathways earnings for the quarter were -$33.39 million. In the same quarter last year, Compass Pathways 's earnings per share (EPS) was -$0.43. If you're new to stock investing, here's how to buy …Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail …And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...

Oct 18, 2023 · Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.

Currently 16 wall-street analysts regularly analyze the financials of Compass Pathways Plc on a frequent basis to provide recommendations along with target share price. 16 analysts offering 12-month price forecasts for Compass Pathways Plc (CMPS) have a share price target of $42.13.WebNext reporting date. March 27, 2024. EPS forecast (this quarter) -$0.22. Annual revenue (last year) $233.0K. Annual profit (last year) -$152.4M.CMPS: Get the latest COMPASS Pathways stock price and detailed information including CMPS news, historical charts and realtime prices. Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Ce...COMP360 Overview (August Company Presentation) Psilocybin is a hallucinogenic chemical found in psychedelic mushrooms. It also is in Phase II clinical trials for the treatment of post-traumatic ...WebStill, if you're looking for an investment, COMPASS Pathways remains the most advanced company in psychedelics in terms of the maturity of its flagship pipeline program. Its psychedelic treatment ...See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.On March 3, 2023 the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III code. The application was titled, “Continuous In-Person Monitoring and Intervention during Psychedelic Medication Therapy.”. CPT III codes are a set of temporary codes assigned to emerging technologies, services and procedures.COMPASS Pathways (CMPS) Fundamentals Checker. Financial metrics are used to evaluate financial stability which helps analysts determine if COMPASS Pathways is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.Nov 29, 2022 · That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ... 9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.

How to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

US20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom. Show more.

18 ก.ย. 2563 ... Stock Forecast / Price Prediction / Prognosis: Compass Pathways Plc - ADR Forecast. Predictions, Comments & Questions.BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $47.0... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Rep...The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebHedge funds don't have many shares in COMPASS Pathways. Our data shows that Atai Life Sciences N.V. is the largest shareholder with 23% of shares outstanding.Analyst Price Forecast Suggests 309.83% Upside. As of April 6, 2023, the average one-year price target for COMPASS Pathways Plc American Depository Shares is $42.38. The forecasts range from a low ...WebAnalyst Price Forecast Suggests 309.83% Upside. As of April 6, 2023, the average one-year price target for COMPASS Pathways Plc American Depository Shares is $42.38. The forecasts range from a low ...Web2 de set. de 2022 ... ... stock could be Wall Street's biggest winner of the 2020s. Listen to the Podcast ➡️Spotify: https://open.spotify.com/show ...Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...CMPS: Get the latest COMPASS Pathways stock price and detailed information including CMPS news, historical charts and realtime prices. Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Ce...Discover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.Dec 1, 2023 · COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Nov 29, 2023 · View COMPASS Pathways PLC Sponsored ADR CMPS investment & stock information. Get the latest COMPASS Pathways PLC Sponsored ADR CMPS detailed stock quotes, stock data, Real-Time ECN, charts, stats ... Oct 30, 2023 · Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ... Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018 Instagram:https://instagram. draft kings in floridatreasury money market fundstechnology etf listwsj movers What this means: InvestorsObserver gives Compass Pathways Plc ADR (CMPS) an overall rank of 34, which is below average. Compass Pathways Plc ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ... vanguard bond fund listi bond rate prediction Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes … is it a good idea to buy land markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …Shares of Compass Pathways PLC pointed north out of the gate, as the first trade was 37.6% above the initial public offering price. The said Friday that it's upsized , above the …